Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 59 of 78 for:    vismodegib

A Study of Oral Vismodegib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02168530
Recruitment Status : Withdrawn
First Posted : June 20, 2014
Last Update Posted : November 2, 2016
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Brief Summary:
This is a randomized, multicenter, double-blind, placebo-controlled, parallel-group study of vismodegib in patients with IPF. Eligible patients will be randomized in a 2:1 ratio to one of two treatment arms: vismodegib or placebo. The duration of treatment will be 52 weeks. Study drug will be administered daily by the oral route. An 8-week safety follow-up period is included for all patients who receive at least one dose of study drug.

Condition or disease Intervention/treatment Phase
Idiopathic Pulmonary Fibrosis Drug: placebo Drug: vismodegib Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Study Start Date : October 2014
Estimated Primary Completion Date : January 2017
Estimated Study Completion Date : January 2017


Arm Intervention/treatment
Placebo Comparator: Placebo Drug: placebo
matching placebo administered daily orally

Experimental: Vismodegib Drug: vismodegib
vismodegib 150 mg administered daily orally




Primary Outcome Measures :
  1. Change in forced vital capacity (FVC) percent predicted [ Time Frame: From baseline to Week 52 ]

Secondary Outcome Measures :
  1. Change in diffusion capacity of the lung for carbon dioxide (DLCO) [ Time Frame: From baseline to Week 52 ]
  2. Annualized rate of change in FVC [ Time Frame: Week 52 ]
  3. Progression-free survival [ Time Frame: Week 52 ]
  4. Time from randomization to first event of acute IPF exacerbation [ Time Frame: Up to 52 weeks ]
  5. Change in Quality of Life measurements [ Time Frame: From baseline to Week 52 ]
  6. Safety: Incidence of adverse events (AEs) [ Time Frame: Approximately 60 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult patients aged >/=40 years at Visit 1
  • Diagnosis of IPF within the previous 5 years from time of screening and confirmed at baseline
  • Patients from countries where a treatment is licensed/approved for IPF must additionally meet at least one of the following criteria to be eligible: (1) be unable to access a licensed therapy for IPF; (2) treatment with a licensed therapy/therapies has been stopped for lack of efficacy or because of safety/tolerability reasons (a washout period will be required); (3) be unwilling to be treated with a licensed therapy and study enrollment considered appropriate.
  • Forced vital capacity (FVC) >/=40% and </=90% of predicted at screening
  • Stable baseline lung function as evidenced by a difference of <10% in absolute FVC measurements (in liters) between screening and Day 1/Visit 2 prior to randomization
  • Diffusion capacity of the lung for carbon dioxide (DLCO) >/=25% of predicted at screening
  • Adequate hematopoietic capacity, liver and renal function
  • Female patients of childbearing potential must use two methods of acceptable contraception, including one highly effective method and a barrier method, during treatment and for 7 months after completion of study treatment (or as per local requirement)
  • Male patients must agree to remain abstinent or use a condom, even after a vasectomy, during sexual intercourse with female partners while being treated with vismodegib/placebo, and for 2 months after completion of study treatment
  • Agreement not to donate blood or blood products during the study and for at least 7 months (or as per local requirements) after the last dose of study treatment

Exclusion Criteria:

  • Pregnant or lactating
  • Known hypersensitivity to any of the study drug excipients or the drug itself
  • Prior treatment with vismodegib or any Hh-pathway inhibitor
  • Evidence of other known causes of interstitial lung disease
  • Hospitalization due to an exacerbation of IPF within 4 weeks prior to, or during, screening
  • Lung transplant expected within 12 months of screening
  • Evidence of clinically significant lung disease other than IPF
  • Substantial emphysema on high resolution computed tomography (HRCT) with degree of emphysema greater than fibrosis
  • Post bronchodilator forced expiratory volume in 1 second/FVC ratio <0.7 at screening
  • Class IV New York Heart Association chronic heart failure or historical evidence of left ventricular ejection fraction <35%
  • Known current malignancy or current evaluation for a potential malignancy
  • Known immunodeficiency, including but not limited to HIV infection
  • Any clinically significant medical disease (other than IPF) that is associated with an expected survival of <12 months, likely to require a change in therapy during the study, or likely to impact the ability of the patient to participate in the study in the opinion of the investigator, or impact the study efficacy or safety assessments

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02168530


Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Layout table for investigator information
Study Director: Clinical Trials Hoffmann-La Roche

Layout table for additonal information
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT02168530     History of Changes
Other Study ID Numbers: GB29298
2014-000963-42 ( EudraCT Number )
First Posted: June 20, 2014    Key Record Dates
Last Update Posted: November 2, 2016
Last Verified: November 2016

Additional relevant MeSH terms:
Layout table for MeSH terms
Fibrosis
Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Idiopathic Interstitial Pneumonias
Pathologic Processes
Lung Diseases
Respiratory Tract Diseases
Lung Diseases, Interstitial